Detalhe da pesquisa
1.
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
N Engl J Med
; 383(15): 1425-1435, 2020 10 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966714
2.
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin.
Diabetes Obes Metab
; 25(3): 758-766, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36394384
3.
Cost-Effectiveness of Medication Therapy Management Program Across Racial and Ethnic Groups Among Medicare Beneficiaries.
Value Health
; 26(5): 649-657, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36376143
4.
Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial.
Am J Nephrol
; 53(7): 516-525, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35691283
5.
The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
Diabetes Obes Metab
; 24(6): 1114-1122, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35233908
6.
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV.
Diabetes Obes Metab
; 24(7): 1245-1254, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35266296
7.
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
Diabetes Obes Metab
; 24(9): 1829-1839, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35603908
8.
Racial and ethnic disparities associated with the measure for drug-drug interactions among Medicare beneficiaries.
J Am Pharm Assoc (2003)
; 62(1): 142-149, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34509379
9.
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
Diabetologia
; 64(6): 1256-1267, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33665685
10.
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies.
Diabetes Obes Metab
; 22(12): 2276-2286, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32700421
11.
Calorie Restriction and Intermittent Fasting: Impact on Glycemic Control in People With Diabetes.
Diabetes Spectr
; 33(2): 143-148, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32425451
12.
Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
Diabetes Obes Metab
; 2024 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38840474
13.
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
Eur Heart J
; 44(48): 5163-5166, 2023 Dec 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37864578
14.
Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial.
Circulation
; 146(8): 652-654, 2022 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35994565
15.
Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
Diabetes Obes Metab
; 20(2): 409-418, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28817231
16.
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
Diabetes Obes Metab
; 20(3): 530-540, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28921862
17.
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
Diabetes Obes Metab
; 25(5): 1398-1402, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36594154
18.
Higher Predictive Value Positive for MMA Than ACA MTM Eligibility Criteria Among Racial and Ethnic Minorities: An Observational Study.
Inquiry
; 55: 46958018795749, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30175638
19.
Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].
Diabetologia
; 65(5): 908-911, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35238955
20.
Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations From VERTIS CV.
Circulation
; 143(6): 602-605, 2021 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33186063